Key Performance
More- Earnings Score: N/A
- Momentum Score: 11
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A lawsuit was filed on July 24, 2026, against PROCEPT BioRobotics Corporation alleging the company misrepresented U.S. handpiece unit sales through an undisclosed discount program that incentivized bulk orders beyond actual demand, artificially inflating reported sales and exposing the company to material operational and financial risks.
09/30/2026, 3:52 PM • GlobeNewswire
Grabar Law Office announced investigations into potential breaches of fiduciary duties by officers and directors at Doximity, GoDaddy, Planet Fitness, and PROCEPT BioRobotics. The investigations follow federal securities class action filings alleging misleading statements regarding business metrics, pricing strategies, and financial guidance. Long-term shareholders meeting specific holding periods are eligible to seek corporate reforms and potential compensation at no cost.
09/24/2026, 9:36 AM • GlobeNewswire
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about its business between February 2024 and February 2026. The company allegedly used an undisclosed discount program to artificially inflate handpiece sales, leading to excess inventory of over 10,000 units. Stock price declined significantly following three earnings announcements revealing lower-than-expected sales and inventory issues. Shareholders have until September 22, 2026 to file lead plaintiff motions.
09/21/2026, 2:40 PM • GlobeNewswire
Kaplan Fox has filed a class action lawsuit against PROCEPT BioRobotics Corporation for allegedly misleading investors about the relationship between handpiece unit sales and procedures. The complaint alleges that undisclosed discount programs artificially inflated reported U.S. handpiece unit sales and revenues by pulling forward demand. Investors who purchased PROCEPT common stock between February 28, 2024 and February 25, 2026 may be eligible to participate in the class action, with a deadline of September 22, 2026 to seek a lead plaintiff role.
09/21/2026, 12:00 PM • GlobeNewswire
A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly misleading investors about handpiece sales through undisclosed bulk discount programs that artificially inflated revenues. The company pulled forward sales from future quarters to meet expectations, resulting in excess customer inventory of over 10,000 units. PROCEPT shares declined over 48% from August 2025 to February 2026 as the truth emerged through a series of earnings misses and subsequent disclosures.
09/19/2026, 4:37 PM • GlobeNewswire
A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding handpiece unit sales and revenues. The lawsuit claims the company used undisclosed discount programs to artificially inflate sales figures, created excess inventory of over 10,000 units, and failed to disclose material risks. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation, with a September 22, 2026 deadline to serve as lead plaintiff.
09/18/2026, 10:59 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Doximity, Inc., PROCEPT BioRobotics Corporation, and DNOW Inc. on behalf of investors who suffered losses. The Doximity lawsuit alleges the company overstated its Newsfeed's revenue impact and lost market share to competitors. Investors with losses exceeding $100,000 are encouraged to seek counsel before upcoming deadlines.
09/18/2026, 10:38 PM • GlobeNewswire
Rosen Law Firm reminds investors in DNOW Inc., PROCEPT BioRobotics Corporation, and Doximity Inc. of upcoming deadlines to join securities class action lawsuits. DNOW faces allegations of false statements regarding merger challenges with MRC Global, while similar class actions have been filed against the other companies. Investors must act by specified deadlines to potentially recover damages.
09/18/2026, 10:28 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Wix.com Ltd., PROCEPT BioRobotics Corporation, and Doximity, Inc. The lawsuits allege that defendants made false and misleading statements regarding product performance, costs, and financial benefits. Investors who purchased securities during specified class periods are encouraged to secure counsel before the September 22, 2026 deadline to potentially join the litigation.
09/18/2026, 10:06 PM • GlobeNewswire
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding its handpiece unit sales and revenues. The company allegedly used an undisclosed extensive discount program to artificially inflate sales by pulling forward orders, creating over 10,000 excess units in field inventory and causing the company to miss its 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 can apply to be lead plaintiff by September 22, 2026.
09/18/2026, 11:00 AM • GlobeNewswire
Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for violations of the Securities Exchange Act. The lawsuit alleges the company made false and misleading statements by using large discounts to inflate current revenue, pulling orders forward, and materially overstating handpiece unit utilization. The class period spans February 28, 2024 to February 25, 2026, with a September 22, 2026 deadline for investors to participate.
09/17/2026, 10:00 AM • GlobeNewswire
A securities class action has been filed against PROCEPT BioRobotics for allegedly misleading investors about handpiece sales performance. The company allegedly used undisclosed bulk order discount programs to artificially inflate sales figures by pulling forward future quarter sales, resulting in excess customer inventory exceeding 10,000 units. The stock declined over 48% from August 2025 to February 2026 as the truth emerged through quarterly earnings misses and management disclosures.
09/16/2026, 4:51 PM • GlobeNewswire
PROCEPT BioRobotics faces a securities fraud class action lawsuit for failing to disclose material inventory issues. The company revealed that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to decline 18% in two days, from $27.84 to $22.69 per share, as quarterly handpiece sales dropped nearly 30% and the company missed annual revenue guidance by tens of millions of dollars. Investors have until September 22, 2026 to file lead plaintiff applications.
09/15/2026, 10:44 PM • GlobeNewswire
Rosen Law Firm is reminding investors in Wix.com Ltd., Papa John's International, Inc., and PROCEPT BioRobotics Corporation of upcoming lead plaintiff deadlines in securities class action lawsuits. The Wix lawsuit alleges the company made false statements about its AI product offerings, overstating competitiveness and understating development costs. Investors who purchased securities during specified class periods may be eligible for compensation.
09/15/2026, 9:24 PM • GlobeNewswire
Rosen Law Firm announces a September 22, 2026 deadline for investors to join a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges the company made materially false statements regarding its handpiece unit sales and revenues, claiming an undisclosed discount program artificially inflated sales figures, created excess inventory of over 10,000 units, and that the company could not achieve its 2025 guidance.
09/15/2026, 8:53 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/01/2026
Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.